Vimarsana
Biggest News Aggregation in the World

Cell Source Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Source Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Source Inc Today - Breaking & Trending Today

Cell Source Announces Resignations of Directors - Vimarsana News

Cell Source Announces Resignations of Directors

/PRNewswire/ -- On July 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of Cell Source, Inc. (the "Company"). Neither Mr....

EnerSpar Corp.: EnerSpar and Israeli-Based Nurexone Announce Definitive Agreement - Vimarsana News

EnerSpar Corp.: EnerSpar and Israeli-Based Nurexone Announce Definitive Agreement

Calgary, Alberta--(Newsfile Corp. - January 18, 2022) - EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) ("EnerSpar" or the "Company") is pleased to announce that they have entered into an arm's length securities

Darlene Soave Joins Cell Source's Board of Directors - Vimarsana News

Darlene Soave Joins Cell Source's Board of Directors

Darlene Soave Joins Cell Source's Board of Directors News provided by Share this article Share this article NEW YORK, April 1, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ("Cell Source" or "the Company"), is the world leader in Veto Cell based innovative immunotherapy and today announced that Darlene Soave has been appointed to the Company's Board of Directors, effective March 25, 2021.  Veto Cells, in different mouse models, have shown that they have the potential to safely facilitate mismatched donor stem cell (e.g. bone marrow) transplants and organ transplants. In addition, in pre...

Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials - Vimarsana News

Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials

/PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the Company"), the world leader in Veto Cell based immunotherapy technologies that can safely...